After decades of near oblivion, thrombin generation is being revived as an overall function test of the plasmatic coagulation system in platelet-poor plasma (PPP). In platelet-rich plasma (PRP) it assesses platelet procoagulant functions as well.
Introduction
Because of its numerous positive and negative feedback controls, the hemostatic-thrombotic system is so complicated that it is practically impossible to judge the overall hemostatic function of the blood from the concentration or structure of its components. Information on details of the system therefore is not an alternative for an overall function test. Clotting times (prothrombin time, activated partial prothrombin time [aPTT] , activated whole blood clotting time) do not indicate hypercoagulability and are insensitive to mild bleeding disorders. For over a century (eg, Hayem [1]), the generation of thrombin in clotting blood or plasma has been used to assess the coagulation system, but only recently have technical developments brought it into reach of the nonspecialized laboratory.
Ex vivo thrombin generation (TG) should be distinguished from in vivo TG, revealed by products of an ongoing clotting process in the body (prothrombin fragment 1-2, D-dimer etc.). Increased in vivo TG indicates an ongoing pathologic process. Increased or decreased ex vivo TG means that the function of the coagulation process is abnormal (eg, hyperprothrombinemia [2] , hemophilia [3••], use of anticoagulants [4] ). It does not necessarily mean ongoing pathology but indicates an increased risk of thrombosis or bleeding [5] . In vivo TG is a smoke detector signaling ongoing evil; ex vivo TG is like the smell of gasoline indicating an increased risk.
The first law of hemostasis and thrombosis
"The more thrombin the less bleeding but the more thrombosis, the less thrombin the less thrombosis but the more bleeding" may be called the "first law of hemostasis and thrombosis." The converse is not true. The cause of thrombosis or bleeding can be in the vessel wall, with the hemostatic function of the blood being perfectly normal. The circumstantial evidence for the first law is overwhelming; we know of no refutation. Bleeding may be caused by a lack of any known clotting factor or by an excess of antithrombin activity (antithrombin Baltimore, heparin); thrombosis by an excess of clotting factor (eg, prothrombin); or a shortage of coagulation delimiters (antithrombin, proteins C and S).
The time course of TG (the "thrombogram") is shown in Figure 1 . After a lag time, a burst of thrombin is observed. Clotting occurs at the end of the lag time, when more than 95% of all thrombin is still to be formed. We Thrombin generation in plasma (in platelet-poor or platelet-rich plasma, PPP or PRP [21, 22] ) represents the function of a relevant slice of the in vivo system with all the plasma proteins present, unmodified, near their physiologic concentrations and independent of a priori hypotheses. It represents a function test of the "isolated organ" PPP or PRP. The vessel wall is lacking, however.
Models of ex vivo thrombin generation
To simulate its presence, the two most important known elements, TF and TM, may be added to the plasma ( Fig.1 ).
Cell-bound thrombin generation: the role of platelets
The arm-to-tongue circulation time of the blood (∼30 seconds) is short compared with a whole blood clotting time, so thrombin formed in flowing blood in vivo is rapidly diluted and inactivated before clotting can occur. Thrombin will only build up in unstirred boundary layers at cell surfaces and in the unstirred plasma caught in a clot or an aggregate. Transport by diffusion will therefore tend to govern reaction rates. According to our interpretation 
Techniques of thrombin generation measurement
The thrombogram can be obtained through subsampling [29] or through monitoring the conversion of a suitable substrate directly added to the clotting plasma [30] . The former method is straightforward and time consuming; 
The thrombogram
Typical thrombograms as obtained with the CAT are shown in Figure 1 . The three most important parameters are the lag time, the peak value, and the area under the curve or endogenous thrombin potential (ETP), which quantifies the enzymatic "work" that thrombin can do during its lifetime ("person-hours" of thrombin) [37] . Plasma clots at the end of the lag phase so the clotting time can be read from the thrombogram. During the lag phase the reaction mechanisms are essentially different from those during the thrombin burst [15]); this is one of the reasons that the clotting time does not represent TG.
The normal values and coefficients of variation as obtained with the CAT-method are given in Table 1 .
Partial techniques
Both the lag time and the ETP can be obtained by alternative techniques without monitoring the complete thrombogram. The clotting time represents the lag time. The ETP can be assessed by measuring the product from any natural or added substrate that is not exhausted during the clotting process. One natural substrate is ␣ 2 M, which, in defibrinated plasma, will bind ∼30% of the thrombin formed (∼5% with fibrinogen). The final concentration of the (amidolytically active) ␣ 2 M-thrombin complex is proportional to the ETP [30] . Rosing et al.
[38] used this approach to demonstrate acquired activated protein C (APC) resistance through the use of oral contraceptives. The ETP can also be assessed by measuring the end level of conversion of a slow-reacting artificial substrate, provided that it does not react with ␣ 2 M-thrombin.
Surrogate techniques of thrombin generation
Several techniques have been published that depend on fibrinogen polymerization. Apart from the clotting time, they give little information on thrombin generation because fibrinogen is exhausted before 5% of all thrombin is formed. In so far as the properties of the clot are determined by the velocity or the amount of thrombin formed, some information can be retained, however. 
Applications of thrombin generation measurement
Thrombin generation measurement has been shown to be a useful tool in several different domains.
Platelet-plasma interactions
Thrombin generation has been instrumental in unveiling the role of platelet receptors in the production of a procoagulant surface by platelets. In short, a role of GPIIb/IIIa, of GPIb/V, and vWF [28•] and of GPI (collagen), as well as of the PAR receptors, has been demonstrated (see Hemker and Lindhout [43] for a review).
Detection and quantification of thrombotic tendency
Deficiencies of proteins S or C are readily recognized when TM is added to the plasma, factor V Leiden as well [44, 45] . APC resistance, either acquired (oral contracep- [55] , and aspirin [56] also inhibit TG to a certain degree. This is not to say that inhibition of aggregation as such would not have an-or even be the main-antithrombotic action. It is an interesting possibility that through decreasing the size of the platelet aggregate, the volume in which thrombin can form undisturbed by flow is also diminished.
Pharmacologic research
As yet we have not encountered any antithrombotic, either anticoagulant or antiaggregant, that did not inhibit TG [5] . We can assume that any drug that inhibits TG to ∼50% of normal will show an antithrombotic effect at an acceptable bleeding risk. By introducing TG as an intermediate step between the biochemical experiments and thrombosis models in experimental animals, we can significantly diminish the latter, especially in dose-finding experiments. The test can also be used to assess the effects of a candidate molecule in volunteers.
Conclusion
To understand thrombin generation, we have to measure thrombin generation, the whole thrombin generation, and nothing but thrombin generation-under conditions as close as possible to those in vivo. This offers a wealth of information that is not otherwise available. Measurement in an undisturbed fibrin clot in which activated platelets are fixed, as is possible with fluorogenic substrates, probably resembles the situation in a hemostatic plug or thrombus more closely than stirred systems do. The calibrated automated technique makes it possible to obtain a graph of thrombin concentration against time in real time in up to 24 parallel experiments. Whole blood measurement is as yet technically impossible.
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